CA-ELEGEN
24.1.2024 14:01:35 CET | Business Wire | Press release
Elegen, a leader in DNA manufacturing innovation, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK) to enable its use of Elegen’s proprietary cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.
The terms of the agreement include upfront fees and purchase commitments of Elegen’s ENFINIA DNA to support GSK’s development of medicines and vaccines, including RNA vaccines. Elegen is also eligible to receive both near-term milestone payments relating to the development of new product features and a potential equity investment in Elegen by GSK.
Commercially launched in March of last year, ENFINIA DNA delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days. Unlike conventional synthesis of mRNA from linearized plasmid DNA, Elegen’s DNA is produced entirely cell-free, with the potential to enable a seamless transition from discovery to clinical scale-up under GMP. This technology may save significant time and substantial resources spent iteratively cloning, linearizing and purifying plasmid DNA as well as generating master cell banks. Elegen’s innovation in cell-free DNA manufacturing technology represents a significant leap forward that could power the next generation of mRNA, cell and gene therapies.
This collaboration follows the Early Access Program launched by Elegen in May of last year that offered DNA of longer length and higher complexity to select customers. “Over the past year dozens of customers, including multiple top 10 biopharma, have validated the unprecedented speed, length, accuracy and complexity of our cell-free DNA manufacturing technology,” said Matthew Hill, Ph.D., Elegen founder and CEO. “GSK recognizes the importance of a reliable, turnkey supply of DNA for a variety of applications for which speed, accuracy and quality of DNA synthesis are essential. This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”
About Elegen
Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com and connect with us on LinkedIn and X (Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124105579/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Can Design the Slides, But It Can’t Fix Stage Fright: 3 in 4 Workers Get Anxious Presenting, Canva Study Finds8.9.2026 15:00:00 CEST | Press release
When AI can build the slides, what sets the presenter apart? Canva's new global study, The Presentation Paradox, finds it comes down to one thing: how you command the room.91% use AI to build and draft presentation slides each month74% feel anxious presenting at work, with Gen Z most affected (90%)68% link strong presentation skills to a recent pay rise or promotion53% currently use AI as a presentation coach55% would let an AI avatar present for them86% say great presentations come down to human connection New research from Canva, the world’s leading visual communication platform, reveals an emerging paradox at the heart of one of work’s age-old skills: even as AI makes presentations easier to create than ever, nearly three in four professionals (74%) still feel anxious about presenting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908549712/en/ Canva's Global 'The Presentation Paradox' Study Few things are as entrench
PAX Debuts The Oxblood Edit, a Limited Edition Collection Inspired by Fall’s Richest Color8.9.2026 15:00:00 CEST | Press release
PAX FOUR, MINI and ERA GO arrive in a deep oxblood finish, bringing timeless style, seasonal color, and elevated design to three of the brand’s signature devices Today PAX, a pioneering global cannabis brand, introduces The Oxblood Edit, an ultra-limited release bringing one of fall’s defining colors to three of the brand’s signature devices: PAX FOUR, PAX MINI and ERA GO. Deep, distinctive and designed to be coveted, Oxblood transforms the PAX lineup through a rich burgundy finish inspired by the worlds of fashion, interiors and industrial design. The limited collection is available beginning today at pax.com and select retailers, while supplies last. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908330141/en/ The Oxblood Edit: bringing timeless style, seasonal color, and elevated design to three of the brand's signature devices. Long associated with craftsmanship and enduring style, oxblood has reemerged across fashion
STARTEEPO Issues Letter and Presentation to the Board of Xerox Calling for Action to Unlock Shareholder Value8.9.2026 15:00:00 CEST | Press release
Urges Strategic Review of Xerox Financial Services, Including Exploring Potential Sale of All or Part of the Business UnitBelieves XFS Business Could Be Worth $7.69 Per Share -- More than Double Xerox’s Current Share PriceAsserts Investors Will Be Better Able to Value XFS Through Increased Transparency STARTEEPO SICAV a.s. (“STARTEEPO”) today issued an investor presentation and the following letter to the Board of Directors (the “Board”) of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX). STARTEEPO, which has increased its investment in Xerox to a beneficial ownership of 7.34%, in stocks and options, is urging the Board to take bold actions to unlock significant shareholder value, including by increasing transparency about Xerox Financial Services’ performance, evaluating strategic alternatives for the business unit, deleveraging the Company, and exercising continued capital discipline. Shareholders can view the investor presentation here. For more information visit
Leblon Delienne Joins LEXON at BOW to Expand Its Global Reach8.9.2026 14:36:00 CEST | Press release
The French sculpture atelier extends the group’s expertise from everyday design to collectible art BOW (Brands of Wonder), the international brand group behind French design brand LEXON, today announced the acquisition of Leblon Delienne, the French sculpture atelier known for transforming pop culture icons into collectible art and design objects. The move pairs the atelier’s distinctive French craftsmanship and licensed collections with BOW’s international reach and digital expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908641342/en/ Leblon Delienne Joins LEXON at BOW Juliette de Blegiers, who acquired the company in 2018, will remain a minority shareholder in Leblon Delienne and continue working alongside BOW founder Boris Brault and the atelier’s teams. For more than 40 years, Leblon Delienne has brought iconic characters to life through sculptures, figurines, furniture, and art and design objects, primarily
Visa Brings Onchain Lending into Everyday Payments8.9.2026 14:00:00 CEST | Press release
By combining VisaNet settlement data with blockchain lending, Visa is helping its partners unlock new financing opportunities for stablecoin-linked card programs. Today, Visa (NYSE: V) announced a new approach to onchain credit designed to help stablecoin-linked card programs and fintechs access working capital using onchain lending infrastructure and Visa data. Onchain lending has emerged as one of the fastest-growing segments of digital finance. According to the Visa Onchain Analytics Dashboard, since 2020, more than $694 billion in stablecoin-denominated loans have been sent through onchain lending protocols, creating a global credit market that operates 24/7. Yet much of that activity remains concentrated within crypto markets and hasn’t meaningfully supported the businesses and payment experiences people use every day. Visa is helping bridge that gap by combining VisaNet settlement data with onchain credit infrastructure. This information can help lenders better understand how a p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom